Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves J&J's Hep C Pill | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

FDA Approves J&J’s Hep C Pill

Olysio shown to cure patients in less time

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The FDA has approved Johnson & Johnson’s Olysio ( assimeprevir) as a treatment for chronic hepatitis C virus infection. Olysio is a protease inhibitor that blocks a specific protein needed by the virus to replicate, and is used in combination with interferon, given by injection, and ribavirin. Olysio was shown in clinical trials to cure patients with a shorter duration of treatment.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics